dc.contributor.author | Lheureux, S | |
dc.contributor.author | Denoyelle, C | |
dc.contributor.author | Ohashi, PS | |
dc.contributor.author | De Bono, JS | |
dc.contributor.author | Mottaghy, FM | |
dc.date.accessioned | 2017-08-14T14:40:57Z | |
dc.date.issued | 2017-08-01 | |
dc.identifier.citation | European journal of nuclear medicine and molecular imaging, 2017, 44 (Suppl 1), pp. 41 - 54 | |
dc.identifier.issn | 1619-7070 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/777 | |
dc.identifier.eissn | 1619-7089 | |
dc.identifier.doi | 10.1007/s00259-017-3695-3 | |
dc.description.abstract | Molecular imaging continues to influence every aspect of cancer care including detection, diagnosis, staging and therapy response assessment. Recent advances in the understanding of cancer biology have prompted the introduction of new targeted therapy approaches. Precision medicine in oncology has led to rapid advances and novel approaches optimizing the use of imaging modalities in cancer care, research and development. This article focuses on the concept of targeted therapy in cancer and the challenges that exist for molecular imaging in cancer care. | |
dc.format | Print-Electronic | |
dc.format.extent | 41 - 54 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | Nuclear Medicine | |
dc.subject | Physicians | |
dc.subject | Molecular Targeted Therapy | |
dc.title | Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-03-27 | |
rioxxterms.versionofrecord | 10.1007/s00259-017-3695-3 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of nuclear medicine and molecular imaging | |
pubs.issue | Suppl 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 44 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
dc.contributor.icrauthor | De Bono, Johann | |